Hemogenyx Pharmaceuticals (HEMO)

Sector:

Pharma and Biotech

1.77p
   
  • Change Today:
      0.005p
  • 52 Week High: 3.96
  • 52 Week Low: 1.17
  • Currency: UK Pounds
  • Shares Issued: 1,341.82m
  • Volume: 1,795,845
  • Market Cap: £23.72m
  • RiskGrade: 340

Hemogenyx enters collaboration agreement with Orgenesis

By Iain Gilbert

Date: Friday 19 Oct 2018

LONDON (ShareCast) - (Sharecast News) - Biopharmaceutical group Hemogenyx has entered into a collaboration agreement with cell therapy outfit Orgenesis to further commercialise its humanised-mouse drug model.
Orgenesis inked the deal with Hemogenyx's Immugenyx subsidiary in order to gain access to its AHC products, a new type of humanised mouse with a functional 'human' immune system used for disease modelling and the development of drugs and cell therapies.

The Maryland-based biopharmaceutical company will advance the London-listed company a convertible loan of at least $1m for the right to market and serve as a distributor of Immugenyx products.

Immugenyx will retain exclusive rights to manufacture, make and supply hematopoietic chimera products to Orgenesis or its affiliates, which will pay Hemogenyx a royalty of 12% of net revenues generated from the technology.

Hemogenyx chief executive Dr Vladislav Sandler, said: "The commercial collaboration, license agreement and investment is an additional confirmation of the uniqueness and value of Immugenyx' AHC platform."

Earlier in the week, Hemogenyx reached a deal with industry giant Johnson and Johnson that will see the pair collaborate on research activities to be determined by a mutually approved research plan.

Immugenyx will own the humanised mouse model and grant Johnson and its affiliates a perpetual, irrevocable, non-exclusive, fully paid-up, transferable, worldwide, license to use the model for their own internal research and product development purposes.

As of 0840 BST, Hemogenyx shares had shot up 12.73% to 3.10p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HEMO Market Data

Currency UK Pounds
Share Price 1.77p
Change Today 0.005p
% Change 0.28 %
52 Week High 3.96
52 Week Low 1.17
Volume 1,795,845
Shares Issued 1,341.82m
Market Cap £23.72m
RiskGrade 340

HEMO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
47.48% below the market average47.48% below the market average47.48% below the market average47.48% below the market average47.48% below the market average
70.37% below the sector average70.37% below the sector average70.37% below the sector average70.37% below the sector average70.37% below the sector average
Price Trend
10.63% below the market average10.63% below the market average10.63% below the market average10.63% below the market average10.63% below the market average
43.86% above the sector average43.86% above the sector average43.86% above the sector average43.86% above the sector average43.86% above the sector average
Income Not Available
Growth Not Available

HEMO Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
09:14 16,379 @ 1.77p
09:14 217,329 @ 1.75p
09:13 16,377 @ 1.77p
09:07 19,401 @ 1.80p
08:55 562,318 @ 1.77p

HEMO Key Personnel

CEO Vladislav Sandler Ph.D.

Top of Page